Document 0570
 DOCN  M9650570
 TI    A multistep procedure for the chemical inactivation of human
       immunodeficiency virus for use as an experimental vaccine.
 DT    9605
 AU    Race E; Stein CA; Wigg MD; Baksh A; Addawe M; Frezza P; Oxford JS;
       Department of Academic Virology, London Hospital Medical College,; UK.
 SO    Vaccine. 1995 Nov;13(16):1567-75. Unique Identifier : AIDSLINE
       MED/96164473
 AB    The kinetics of inactivation of four different strains of HIV-1 (RF, MN,
       SF2 and IIIB) by beta-propiolactone (BPL) and binary ethylenimine (BEI)
       were studied under various conditions. The conditions that would be
       required for the reduction of virus infectivity by at least 10(20)
       TCID50 ml-1 were estimated on the basis of the experimental rates of
       inactivation obtained. A multiple step procedure including treatment
       with 0.2% BPL, 0.05% sodium cholate, 10 mM BEI and 0.02% formaldehyde
       was designed to inactivate HIV-1 for use as an experimental vaccine.
       Complete inactivation of virus infectivity was confirmed by prolonged
       cell culture. The experimental vaccine preparation was analysed for the
       presence of HIV-1 proviral DNA utilizing the polymerase chain reaction.
       After treatment with both BPL and BEI proviral DNA was detected in one
       of four samples using primers encoding a 244 bp segment of the pol
       region of the viral genome. Proviral DNA could not be detected in any of
       the four samples using primers encoding segments of > 400 bp in the gag
       and reverse transcriptase region.
 DE    Aziridines/*PHARMACOLOGY  AIDS Vaccines/*PHARMACOLOGY  Comparative Study
       DNA, Viral/DRUG EFFECTS  Enzyme-Linked Immunosorbent Assay  Human  HIV
       Antigens/ANALYSIS/IMMUNOLOGY  HIV Core Protein p24/ANALYSIS/IMMUNOLOGY
       HIV Envelope Protein gp120/ANALYSIS/IMMUNOLOGY/PHARMACOLOGY  HIV-1/*DRUG
       EFFECTS/GROWTH & DEVELOPMENT/*IMMUNOLOGY  Propiolactone/*PHARMACOLOGY
       Support, Non-U.S. Gov't  Vaccines, Inactivated/PHARMACOLOGY  Virus
       Activation/*DRUG EFFECTS  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).